Nuvation Bio (NUVB) Interest Coverage Ratio (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Interest Coverage Ratio of 0.58 for Q1 2026, up 100.87% year-over-year from 0.29 in Q1 2025, and up 117.23% quarter-over-quarter from 3.36 in Q4 2025.
Nuvation Bio (NUVB) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Interest Coverage Ratio for 7 consecutive years, with 0.58 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 100.87% year-over-year to 0.58; the TTM figure through Mar 2026 stood at 6.4 (up 99.1% YoY), while the FY2025 annual figure was 0.47, up 81.0% from the prior year.
- Interest Coverage Ratio improved to 0.58 in Q1 2026 per NUVB's latest filing, from 3.36 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.58 in Q1 2026 and bottomed at 606.09 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 63.73 across 5 years, with a median of 7.85 in 2023.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio plunged 1139.67% — and 2026, when it surged 100.87%.
- Nuvation Bio's Interest Coverage Ratio stood at 4.34 in 2022, then slumped by 81.48% to 7.87 in 2023, then tumbled by 7601.82% to 606.09 in 2024, then surged by 99.45% to 3.36 in 2025, then soared by 117.23% to 0.58 in 2026.
- Business Quant data shows NUVB's Interest Coverage Ratio at 0.58 in Q1 2026, 3.36 in Q4 2025, and 8.64 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | -7.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.55 |
| Mar 31, 2026 | 0.58 |
| Dec 31, 2025 | -3.36 |
| Sep 30, 2025 | -8.64 |
| Jun 30, 2025 | -19.41 |
| Mar 31, 2025 | -66.60 |
| Dec 31, 2024 | -606.09 |
| Sep 30, 2024 | -67.46 |
| Jun 30, 2024 | -146.04 |
| Mar 31, 2024 | -5.37 |
| Sep 30, 2023 | -7.87 |
| Mar 31, 2023 | -7.85 |
| Dec 31, 2022 | -4.34 |
| Sep 30, 2022 | -3.61 |
| Jun 30, 2022 | -5.38 |
| Mar 31, 2022 | -4.48 |
| Dec 31, 2021 | -17.27 |
| Sep 30, 2020 | -74.97 |